|
業務類別
|
Biotechnology |
|
業務概覽
|
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects. |
| 公司地址
| 800 Chesapeake Drive, Redwood City, CA, USA, 94063 |
| 電話號碼
| +1 617 984-6300 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.maplightrx.com |
| 員工數量
| 133 |
| Mr. Jonathan Gillis |
Chief Administrative Officer, interim Chief Financial Officer and Chief Accounting Officer |
-- |
18/06/2026 |
| Dr. Christopher A. Kroeger, M.D. |
Chief Executive Officer, President and Director |
美元 655.25K |
29/04/2026 |
| Dr. James Lillie, PhD |
Chief Scientific Officer |
-- |
29/04/2026 |
| Mr. Kristopher L. Hanson |
General Counsel |
-- |
29/04/2026 |
| Dr. Erin Pennock Foff, M.D.,PhD |
Chief Medical Officer |
美元 531.00K |
29/04/2026 |
| Dr. Anatol Kreitzer, PhD |
Chief Discovery Officer |
-- |
29/04/2026 |
|
|
| Mr. Martin Babler |
Director |
24/06/2026 |
| Mr. George Pavlov |
Chairman of the Board |
29/04/2026 |
| Dr. Nanna Liebach Luneborg, PhD |
Independent Director |
29/04/2026 |
| Mr. Troy M. Cox, M.B.A. |
Director |
24/06/2026 |
| Dr. Christopher A. Kroeger, M.D. |
Chief Executive Officer, President and Director |
29/04/2026 |
| Ms. Maria C. Walker |
Independent Director |
29/04/2026 |
| Dr. Timothy John Garnett, M.B.B.S. |
Independent Director |
29/04/2026 |
|
|
|
|
